Last $74.45 USD
Change Today -0.04 / -0.05%
Volume 855.8K
BAX On Other Exchanges
Symbol
Exchange
New York
Berlin
SIX Swiss Ex
Mexico
As of 5:15 PM 12/24/14 All times are local (Market data is delayed by at least 15 minutes).

baxter international inc (BAX) Snapshot

Open
$74.23
Previous Close
$74.49
Day High
$74.78
Day Low
$74.09
52 Week High
07/23/14 - $77.31
52 Week Low
03/17/14 - $66.34
Market Cap
40.4B
Average Volume 10 Days
2.6M
EPS TTM
$4.65
Shares Outstanding
542.0M
EX-Date
12/3/14
P/E TM
16.0x
Dividend
$2.08
Dividend Yield
2.75%
Current Stock Chart for BAXTER INTERNATIONAL INC (BAX)

baxter international inc (BAX) Related Businessweek News

View More BusinessWeek News

baxter international inc (BAX) Details

Baxter International Inc. develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney diseases, trauma, and other chronic and acute medical conditions. Its BioScience segment processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; biosurgery products; and certain vaccines. The company’s Medical Products segment manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, and inhalation anesthetics; products and services related to pharmacy compounding, drug formulation, and packaging technologies; and technologies and therapies for peritoneal dialysis, in-center and home hemodialysis, and continuous renal replacement therapy. It sells its products through its direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers to hospitals, kidney dialysis and rehabilitation centers, nursing homes, doctors’ offices, clinical and medical research laboratories, and patients. The company has collaboration with Cell Therapeutics, Inc. to develop and commercialize pacritinib; Coherus Biosciences, Inc. and Momenta Pharmaceuticals, Inc. to develop and commercialize biosimilars; JW Holdings Corporation for parenteral nutritional products containing a formulation of omega 3 lipids; Onconova Therapeutics, Inc. for rigosertib, an anti-cancer compound; and Chatham Therapeutics, LLC to develop and commercialize product for the treatments of hemophilia B. It operates in the United States, Europe, the Middle East, Africa, the Asia-Pacific, Latin America, and Canada. The company was founded in 1931 and is based in Deerfield, Illinois.

61,000 Employees
Last Reported Date: 02/21/14
Founded in 1931

baxter international inc (BAX) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.5M
Chief Financial Officer and Corporate Vice Pr...
Total Annual Compensation: $687.7K
Corporate Vice President and President of Int...
Total Annual Compensation: $771.2K
Corporate Vice President and President of Bio...
Total Annual Compensation: $742.3K
Compensation as of Fiscal Year 2013.

baxter international inc (BAX) Key Developments

Baxter International Inc. Submits Application for U.S. FDA Approval of BAX111

Baxter International Inc. announced that it has submitted a biologics license application (BLA) to the United States (U.S.) Food and Drug Administration (FDA) for the approval of BAX111, the first highly-purified recombinant von Willebrand Factor (rVWF) in clinical development as a treatment for patients with von Willebrand disease, the most common type of inherited bleeding disorder. The filing was based on the completion of a Phase III, multi-center, open-label clinical trial assessing the safety, efficacy and pharmacokinetics of BAX111. The study met its primary efficacy endpoint defined by the number of patients who achieved treatment success for control of bleeding episodes. All patients treated in the full analysis set (n=22) experienced a 100% treatment success rating based on a 4-point efficacy rating scale, comparing prospectively estimated number of infusions needed to treat the bleeding episodes to the actual number of infusions administered. The median number of infusions required to treat bleeding events in the trial was 1.0 and the majority of events (81.1%) were resolved with a single infusion. A total of 125 adverse events (AE's) following 318 infusions occurred in 25/37 subjects. Eight AEs were considered causally related to BAX111: six non-serious related AEs (tachycardia, infusion site paresthesia, electrocardiography (ECG) T-wave inversion, dysgeusia, generalized pruritis and hot flush) occurred in four patients, and two related SAEs (chest discomfort and increased heart rate) occurred in one patient. Both the European Commission and the U.S. Food and Drug Administration have granted orphan-drug designation for BAX111.

Baxter International Inc. Submits Application for U.S. FDA Approval of BAX 855, Extended Half-Life Recombinant FVIII Based on ADVATE for Hemophilia A

Baxter International Inc. announced that the company has submitted a biologics license application (BLA) to the United States Food and Drug Administration (FDA) for the approval of BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment for hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)]. The submission is based on positive results from a prospective, global, multi-center, open-label, two-arm Phase 3 study of 137 previously treated patients (PTP). The results demonstrated that BAX 855 met its primary endpoint in the control and prevention of bleeding episodes and routine prophylaxis for patients who were 12 years or older. Patients in a twice-weekly prophylaxis arm experienced a 95% reduction in median ABR as compared to those in the on-demand arm (1.9 vs. 41.5, respectively). BAX 855 was also effective in treating bleeding episodes, 96% of which were controlled with one or two infusions. No patients developed inhibitors to BAX 855 and no treatment-related serious adverse events, including hypersensitivity, were reported. The most common (three patients) product-related adverse reaction was headache. Baxter expects to present additional data from the BAX 855 pivotal trial in the coming months. The continuation study remains ongoing for patients who completed the pivotal trial and the Phase 3 study among previously treated patients under the age of 12 with severe hemophilia A is progressing. Once the pediatric study is complete, Baxter expects to file for marketing authorization with the European Medicines Agency in 2016. Upon approval, BAX 855 is expected to be produced at the company's Singapore manufacturing facility, one of several sites currently approved for ADVATE production.

Baxter International Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-02-2014 01:00 PM

Baxter International Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-02-2014 01:00 PM. Venue: The New York Palace Hotel, 455 Madison Ave, New York, NY 10022, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BAX:US $74.45 USD -0.04

BAX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Covidien PLC $103.35 USD +0.57
Danone SA €54.32 EUR -0.20
Kimberly-Clark Corp $117.77 USD -0.21
Stryker Corp $96.00 USD -0.61
Takeda Pharmaceutical Co Ltd ¥5,057 JPY -7.00
View Industry Companies
 

Industry Analysis

BAX

Industry Average

Valuation BAX Industry Range
Price/Earnings 22.3x
Price/Sales 2.4x
Price/Book 4.8x
Price/Cash Flow 21.6x
TEV/Sales 1.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BAXTER INTERNATIONAL INC, please visit www.baxter.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.